You are here

Article Text

Article menu
Download PDFPDF
Miscellanea
Journal club
Economic evaluation of a pneumococcal vaccine in a high-risk population
  1. Sushil Agarwal
  1. Correspondence to Dr Sushil Agarwal, ST7 – Respiratory Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Coventry CV2 2DX, UK; drsushilagarwal{at}yahoo.com

https://doi.org/10.1136/thoraxjnl-2013-203449

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    This economic evaluation study was performed to estimate the cost effectiveness of a 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in a high-risk population. Herd immunity has developed as a result of pneumococcal serotypes used in 7-valent pneumococcal conjugate vaccine in infants. Assuming a similar effect with 13-valent pneumococcal conjugate vaccine would mean a …

    View Full Text

    Footnotes

    • Provenance and peer review None.